Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dechra Pharmaceuticals
Public (LSEDPH)
Industry Pharmaceuticals
Founded 1997
Headquarters Northwich, United Kingdom
Key people
Michael Redmond, (Chairman)
Ian Page, (CEO)
Products Felimazola, Vetoryl
Revenue £193.6 million (2014)[1]
£42.2 million (2014)[1]
£59.0 million (2014)[1]
Website www.dechra.com

Dechra Pharmaceuticals plc is an English-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History[edit]

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]

Operations[edit]

The Company sells pharmaceuticals - mainly for dogs, cats and horses; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]

See also[edit]

References[edit]

  1. ^ a b c "Annual Report 2014". Dechra Pharmaceuticals. Retrieved 28 March 2015. 
  2. ^ a b Montague Private Equity announces sale of VetXX
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015. 
  4. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014. 
  5. ^ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015. 

Template:Northwich